Global Mineral And Bone Disorder Treatment Market, By Type (Biphosphates, Estrogens, Phosphate Binders, Non-Calcium, Non-Metal Based Binders and Magnesium Based Binders), Treatment (Diet, Nutrition, Medication, Supplements and Dialysis), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Mineral And Bone Disorder Treatment Market Analysis and Size
The mineral and bone disorder treatment market is forecasted to secure a rising growth with the increasing incidence of metabolic disorders and chronic kidney diseases (CDKs). It is estimated that most people above 50 years are suffering from osteoporosis while a closer count of the people could be at the risk of developing the bone disease. Global bone and mineral metabolism disorders treatment market is continue to witness positive growth due to the increased frequency of Chronic Kidney Diseases (CKD) and metabolic diseases. According to National Kidney Foundation (NKF), CKD in US was 13.5% in 2010.
Data Bridge Market Research analyses a growth rate in the mineral and bone disorder treatment market in the forecast period 2023-2030. The expected CAGR of mineral and bone disorder treatment market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 3.02 billion in 2022, and it would grow up to USD 5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Mineral And Bone Disorder Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Biphosphates, Estrogens, Phosphate Binders, Non-Calcium, Non-Metal Based Binders and Magnesium Based Binders), Treatment (Diet, Nutrition, Medication, Supplements and Dialysis), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Lilly (U.S.), Amgen Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Mineral and bone is a disorder which is characterized by abnormal hormone levels and kidney failure. This causes improper functioning of vitamin D metabolism and leads to abnormalities in calcium, phosphorous and parathyroid hormone levels. Metal and bone disorders also includes calcifications of vascular and other soft tissues in kidney. Thus, the miner and bone disorders can cause serious chronic kidney diseases, if left untreated. Common symptoms include bone pain, heart problems, itchy skin, blocked blood vessels , nerve problems, anaemia and difficulty fighting against germs.
Global Mineral And Bone Disorder Treatment Market Dynamics
Drivers
- Increased Incidence of Osteoporosis
Growing incidence of osteoporosis are projected to boost the market growth during the forecast period 2023-2030. For instance, as per the National Osteoporosis Foundation (NOF) records, around 54 million people in America have osteoporosis. The increase in the osteoporosis disease pose a huge demand for the osteoporosis drugs. Thus, it boosts the market growth.
- Higher Drug Approvals By Several Market Players
More and more drug approvals lead to the increase in th market growth. For instance, in 2010, the FDA approved a monoclonal antibody named Denosumab for treating patients suffering from postmenopausal women at high risk of fractures. Additionally, Teriparatide is a synthetic parathyroid hormone form and the only FDA-approved anabolic. Phosphate binding agents and dialysis are also used in the treatment of hyperphosphatemia. This boost the market growth.
Opportunities
- Increased Elderly Population
Increasing number of elderly populations are suffering from osteoporosis disease. There is very huge growth in osteoporosis disease in geriatric population. For instance, according to The National Osteoporosis Foundation (NOF) reports, around one out of two women and one out of four men aged 50 and above is suffering from a bone break because of osteoporosis and other bone related disorder. This creates opportunity for the market expansion.
- Increasing Demand for Retail Pharmacies
The rise in the number of mineral and bone disorder treatment delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Risk of Side-Effects
The varied side-effects that are associated with mineral and bone disorder treatment could restrain the growth of the global mineral and bone disorder treatment market over a forecast period. Side-effects such as dyspepsia and headache, and to a lesser extent, myalgia, low-back pain, flushing, and rhinitis are visible with the use of mineral and bone disorder treatment.
- High Cost
The huge expenditure associated with these agents hamper the market growth. Several surgeries, medications are hampering the growth of the market.
This mineral and bone disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mineral and bone disorder treatment contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Mineral And Bone Disorder Treatment Market Scope
The mineral and bone disorder treatment market is segmented on the basis of type, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Biphosphates
- Estrogens
- Phosphate Binders
- Non-Calcium
- Non-Metal Based Binders
- Magnesium Based Binders
Treatment
- Diet
- Nutrition
- Medication
- Supplements
- Dialysis
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mineral And Bone Disorder Treatment Market Regional Analysis/Insights
The mineral and bone disorder treatment market is analyzed and market size insights and trends are provided by type, treatment, distribution channel and end-user as referenced above.
The major countries covered in the mineral and bone disorder treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for mineral and bone disorder treatment market throughout the forecasted period due to increased new research and developments on mineral and bone disorder treatment
North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mineral And Bone Disorder Treatment Market Share Analysis
The mineral and bone disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mineral and bone disorder treatment market
Key players operating in the mineral and bone disorder treatment market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland.)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- Melinta Therapeutics, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
SKU-